Biogen (BIIB) Morgan Stanley 24th Annual Global Healthcare Conference summary

Strategic transformation and capital allocation

• Shifted from a neuroscience-focused, high-risk model to a diversified portfolio across neurology, immunology, nephrology, rheumatology, dermatology, and retina specialties, driven by targeted business development and acquisitions.

• Currently running 10 phase III clinical trials, with potential for eight product launches across five molecules, aiming for significant revenue inflection, especially with the Apellis acquisition.

• Focused on early-stage development and capital-efficient acquisitions, leveraging expanded access to early-stage assets, particularly in immunology.

• Broadened commercial and medical affairs teams to support new therapeutic areas, with ongoing build-out into 2027, especially for lupus and rare diseases.

• Emphasizes a portfolio approach in immunology and lupus, with multiple assets and mechanisms to address heterogeneous patient needs.

Alzheimer's disease and LEQEMBI updates

• Uptake of LEQEMBI has been slower than expected due to care pathway complexity, but adoption is improving with blood-based diagnostics and subcutaneous formulations.

• Subcutaneous LEQEMBI for induction and maintenance is expected to drive market share and growth, with broader reimbursement anticipated from January 1st.

• Early treatment studies (AHEAD 3-45) are fully recruited, with readout expected in 2028, aiming to demonstrate benefits in early-stage patients and potentially reshape the market.

• Competitive landscape remains focused on two main molecules for the foreseeable future, with ongoing efforts to improve efficacy and ARIA rates.

Lupus and immunology pipeline

• Two phase III SLE studies for litifilimab expected to read out in Q4, with CLE phase III data in 2027; patient selection and lessons from MS are key to trial design.

• Market opportunity for lupus estimated at $8 billion globally, with growth expected as biologic penetration increases and multiple drugs address diverse patient needs.

• Additional assets in lupus include dapirolizumab (partnered with UCB) and an IRAK4 degrader, supporting a multi-product strategy.